Search for metastasis-related proteins in colorectal cancer by proteome analysis

通过蛋白质组分析寻找结直肠癌转移相关蛋白

• 批准号: 23790216
• 负责人: NAGANO Kazuya
• 金额: $ 2.75万
• 依托单位: 独立行政法人医薬基盤研究所
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23790216/
• 关键词: 医療薬剤学; プロテオミクス; 癌; 蛋白質; 生体分子; 薬学; バイオマーカー; 転移

Since metastasis is one of the most important prognostic factors in colorectal cancer, development of novel diagnostic and preventive methods for metastasis is highly desirable. However, the molecular mechanism of the metastatic phenotype has not been well elucidated. In this regard, we searched for metastasis-related proteins in colorectal cancer by analyzing the differential expression of proteins between primary and metastasis focus-derived colorectal tumor cells using a proteomics-based study. In order to validate these candidate proteins, we analyzed the expression profile of these proteins in tissue microarray. As a result, Rho GDP-dissociation inhibitor (Rho GDI) was identified as a metastasis-related protein in colon cancer patients. Consequently, Rho GDI may be useful for a diagnostic or preventive target against colon cancer metastasis.

由于转移是结直肠癌最重要的预后因素之一，因此非常需要开发新的转移诊断和预防方法。然而，转移表型的分子机制尚未得到很好的阐明。在这方面，我们通过基于蛋白质组学的研究分析原发性和转移灶来源的结直肠肿瘤细胞之间蛋白质的差异表达来寻找结直肠癌中与转移相关的蛋白质。为了验证这些候选蛋白，我们分析了这些蛋白在组织微阵列中的表达谱。结果，Rho GDP 解离抑制剂（Rho GDI）被确定为结肠癌患者中的转移相关蛋白。因此，Rho GDI 可能有助于作为结肠癌转移的诊断或预防目标。

项目成果

Rho GDP-dissociation inhibitor alpha is associated with cancer metastasis in colon and prostate cancer

Rho GDP 解离抑制剂 α 与结肠癌和前列腺癌的癌症转移相关

• 发表时间: 2012
• 影响因子: 1.6
• 作者: Yamashita T.; Okamura T.; Nagano K.; Imai S.; Abe Y.; Nabeshi H.; Yoshikawa T.; Yoshioka Y.; Kamada H.; Tsutsumi Y.; Tsunoda S
• 通讯作者: Tsunoda S